Skip to content
etf.net

Launched · SEC filings

Portfolio Building Block World Pharma and Biotech Index ETF

PBPHNasdaqPortfolio Building Block ETFsB

$31.16−0.19 (−0.61%)

At close: Nov 2, 2026, 4:00 PM ET

B65/ 100

Rank 4 of 9 in Pharma & Therapeutics

B65/100Rank 4 of 9inPharma & Therapeutics
Intraday session: down, 79 prints from 31.35 to 31.16. Range 31.07 to 31.31. Use the arrow keys to read each point.31.1031.2031.2531.3010 AM12 PM2 PM4 PM
Expense ratio
0.13%
Fund size
$1.18B
1Y total return
No data
Yield · Last 12 months
No data
Holdings
54
Avg volume · 30D
138K sh
52W range
low $24.18high $31.64
Launched
Filings
SEC EDGAR

The ETF.net PBPH Grade

Based on 5 of 6 pillars

B

Score 65 out of 100

Category
Pharma & Therapeutics⁠
Rank
4 of 9
Six-pillar profile for PBPH. Scores out of 100: Cost 94, Risk 56, Mission not scored, Tradability 37, Holdings 40, Durability 51. Strongest: Cost (94). Weakest: Tradability (37). Based on 5 of 6 pillars.

Score 65 of 100 falls in the B band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    A94 out of 100
    Rank 1 of 9

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    Not scored

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    B56 out of 100
    Rank 5 of 9

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    D37 out of 100
    Rank 6 of 9

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    C40 out of 100
    Rank 7 of 9

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    C51 out of 100
    Rank 6 of 9

Our read on PBPH

ETF.net Research

In short

BMost biotech funds stop at the US border. PBPH buys the developed world's drug complex, pharma and biotech together, through a plain index fund charging 0.13%.

Stated mandate

The Fund seeks to track, before fees and expenses, the performance of the BITA Global Pharma and Biotech Select Index.

Why people hold it

  • 0.13% a year, in a global thematic aisle where the typical fund charges several times that. Fee drag is about as small as this shelf gets.
  • Pharma and biotech under one ticker, global rather than US-only, so overseas drugmakers sit alongside the American names.portfoliobuildingblocketfs.com
  • Straight index replication inside an ordinary 1940 Act fund. Published rules do the picking, not a manager's hunch.
  • Cheap build plus workable trading puts it among the stronger implementations in its global thematic peer group.

Worth knowing

  • One industry, one storyline. Drug pricing rules, patent cliffs and trial readouts swing this basket in ways the broad market does not feel.
  • Launched in late 2025, so there is no long live record showing how closely it hugs the index across a full cycle.
  • Cash comes back once or twice a year, not monthly. This is an exposure holding, not an income schedule.

PBPH Performance

Launched Nov 24, 2025

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

Not enough history yet.Not enough history yet.Not enough history yet.Not enough history yet.
PBPH$12,421
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,169
Dec 31, 2025 to Oct 30, 2026. PBPH $12,421. SPY $11,169. Use the arrow keys to read each point.$10,000$11,000$12,000Dec 2025Jun 2026Oct 2026

Dec 31, 2025 – Oct 30, 2026

Returns run to the Oct 30, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for PBPH. Periods over one year show the average yearly return.
PeriodPBPH
Year to date+24.2%
1 month+10.4%
3 months+15.3%
1 yearFund is under 1 year oldNo data
3 yearsFund is under 3 years oldper yearNo data
5 yearsFund is under 5 years oldper yearNo data
10 yearsFund is under 10 years oldper yearNo data

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for PBPH
YearReturn barPBPH
2026 YTD+24.2%
2025+0.7%

History from Nov 25, 2025

PBPH in the news

PBPH Dividends

Last payment
$0.02 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Irregular

Distribution data unavailable.

Distribution history

2025–2026

One bar per payment. 1 payment from 2025 to 2026 YTD. Dec 24, 2025 $0.02. Use the arrow keys to read each point.20252026YTD
Ex-datePay dateAmount per share
Dec 24, 2025Dec 26, 2025$0.02

PBPH Risk

Risk pillarB56 out of 100Rank 5 of 9 in Pharma & Therapeutics
How much the fund’s monthly returns vary, scaled to a year.
Launched Nov 2025; fills in after 12 months
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
Launched Nov 2025; fills in after 12 months
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
Launched Nov 2025; fills in after 12 months
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.05
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

PBPH Cost

Cheapest in Pharma & Therapeutics

$2,726

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • PBPH 0.13%

    $2,726

$10,000
30 years

Cost over time

  • PBPH 0.13%
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$1K$2K$3K051015202530PBPH $2,726

Year by year

YearPBPH
10$238
20$930
30$2,726

Other funds in Pharma & Therapeutics

See others